Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve... Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. Show more
Published data show that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 sexual experiences. Use of topical Sildenafil Cream, 3.6% did not...
Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method could be used to assess treatment efficacy...
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase...
SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at...
SAN DIEGO, July 19, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, announced that it was notified by the Nasdaq...
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health...
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.06 | -1.82370820669 | 3.29 | 3.4212 | 3.22 | 14844 | 3.27228368 | CS |
4 | -0.32 | -9.01408450704 | 3.55 | 3.75 | 3.22 | 29424 | 3.46388329 | CS |
12 | -1.4104 | -30.3939315576 | 4.6404 | 5.028 | 3.05 | 127400 | 4.04131905 | CS |
26 | -3.01 | -48.2371794872 | 6.24 | 7.56 | 3.05 | 407841 | 4.42644454 | CS |
52 | -2.47 | -43.3333333333 | 5.7 | 7.56 | 3.05 | 431411 | 4.48769672 | CS |
156 | -17.53 | -84.4412331407 | 20.76 | 30.12 | 3.05 | 1029888 | 17.73646639 | CS |
260 | -7.1524 | -68.8896594236 | 10.3824 | 46.2 | 3.05 | 1489986 | 19.66699872 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.